WHO Grade 3 Glioma Recruiting Phase 2 Trials for Dabrafenib (DB08912)

Also known as: WHO Grade III Gliomas / Grade III Glioma / WHO Grade III Glioma

IndicationStatusPhase
DBCOND0146359 (WHO Grade 3 Glioma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03919071Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaTreatment